Interaction between NO and COX pathways in retinal cells exposed to elevated glucose and retina of diabetic rats.

A nonselective inhibitor of cyclooxygenase (COX; high-dose aspirin) and a relatively selective inhibitor of inducible nitric oxide synthase (iNOS; aminoguanidine) have been found to inhibit development of diabetic retinopathy in animals, raising a possibility that NOS and COX play important roles in the development of retinopathy. In this study, the effects of hyperglycemia on retinal nitric oxide (NO) production and the COX-2 pathway, and the interrelationship of the NOS and COX-2 pathways in retina and retinal cells, were investigated using a general inhibitor of NOS [N(G)-nitro-l-arginine methyl ester (l-NAME)], specific inhibitors of iNOS [l-N(6)-(1-iminoethyl)lysine (l-NIL)] and COX-2 (NS-398), and aspirin and aminoguanidine. In vitro studies used a transformed retinal Müller (glial) cell line (rMC-1) and primary bovine retinal endothelial cells (BREC) incubated in 5 and 25 mM glucose with and without these inhibitors, and in vivo studies utilized retinas from experimentally diabetic rats (2 mo) treated or without aminoguanidine or aspirin. Retinal rMC-1 cells cultured in high glucose increased production of NO and prostaglandin E(2) (PGE(2)) and expression of iNOS and COX-2. Inhibition of NO production with l-NAME or l-NIL inhibited all of these abnormalities, as did aminoguanidine and aspirin. In contrast, inhibition of COX-2 with NS-398 blocked PGE(2) production but had no effect on NO or iNOS. In BREC, elevated glucose increased NO and PGE(2) significantly, whereas expression of iNOS and COX-2 was unchanged. Viability of rMC-1 cells or BREC in 25 mM glucose was significantly less than at 5 mM glucose, and this cell death was inhibited by l-NAME or NS-398 in both cell types and also by l-NIL in rMC-1 cells. Retinal homogenates from diabetic animals produced significantly greater than normal amounts of NO and PGE(2) and of iNOS and COX-2. Oral aminoguanidine and aspirin significantly inhibited all of these increases. The in vitro results suggest that the hyperglycemia-induced increase in NO in retinal Müller cells and endothelial cells increases production of cytotoxic prostaglandins via COX-2. iNOS seems to account for the increased production of NO in Müller cells but not in endothelial cells. We postulate that NOS and COX-2 act together to contribute to retinal cell death in diabetes and to the development of diabetic retinopathy and that inhibition of retinopathy by aminoguanidine or aspirin is due at least in part to inhibition of this NO/COX-2 axis.

[1]  M. Rosa,et al.  Modulation of the induction of nitric oxide synthase by eicosanoids in the murine macrophage cell line J774 , 1992, British journal of pharmacology.

[2]  P. Hardy,et al.  Oxidants, nitric oxide and prostanoids in the developing ocular vasculature: a basis for ischemic retinopathy. , 2000, Cardiovascular research.

[3]  C. Wei,et al.  Interaction between nitric oxide and prostaglandin H synthase. , 1994, Archives of biochemistry and biophysics.

[4]  J. Roberts,et al.  Nitric oxide produced by endothelial cells increases production of eicosanoids through activation of prostaglandin H synthase. , 1995, Circulation research.

[5]  M. Currie,et al.  A fluorometric assay for the measurement of nitrite in biological samples. , 1993, Analytical biochemistry.

[6]  M. Katori,et al.  Evaluation of pharmacological profile of meloxicam as an anti-inflammatory agent, with particular reference to its relative selectivity for cyclooxygenase-2 over cyclooxygenase-1. , 1997, Pharmacology.

[7]  A. Baldwin,et al.  Positive and negative regulation of NF-kappaB by COX-2: roles of different prostaglandins. , 2001, The Journal of biological chemistry.

[8]  K. Decker,et al.  Regulation by prostaglandin E2 of cytokine-elicited nitric oxide synthesis in rat liver macrophages. , 1992, Biological chemistry Hoppe-Seyler.

[9]  H. Itoh,et al.  Induction of apoptosis in bovine articular chondrocyte by prostaglandin E(2) through cAMP-dependent pathway. , 2000, Osteoarthritis and cartilage.

[10]  I. Charles,et al.  Purification and characterization of the constitutive nitric oxide synthase from human placenta. , 1994, Archives of biochemistry and biophysics.

[11]  J. Pelletier,et al.  The Induction of Cell Death in Human Osteoarthritis Chondrocytes by Nitric Oxide Is Related to the Production of Prostaglandin E2 Via the Induction of Cyclooxygenase-2 , 2000, The Journal of Immunology.

[12]  G. Romeo,et al.  Response of capillary cell death to aminoguanidine predicts the development of retinopathy: comparison of diabetes and galactosemia. , 2000, Investigative ophthalmology & visual science.

[13]  P. Needleman,et al.  Interactions between the inducible cyclooxygenase (COX-2) and nitric oxide synthase (iNOS) pathways: implications for therapeutic intervention in osteoarthritis. , 1999, Osteoarthritis and cartilage.

[14]  S. Cuzzocrea,et al.  Oxidation, tyrosine nitration and cytostasis induction in the absence of inducible nitric oxide synthase. , 1998, International journal of molecular medicine.

[15]  M. Currie,et al.  Synthesis and biological characterization of L-N(6)-(1-iminoethyl)lysine 5-tetrazole-amide, a prodrug of a selective iNOS inhibitor. , 2002, Journal of medicinal chemistry.

[16]  C. Fang,et al.  Expression of constitutive cyclo-oxygenase (COX-1) in rats with streptozotocin-induced diabetes; effects of treatment with evening primrose oil or an aldose reductase inhibitor on COX-1 mRNA levels. , 1997, Prostaglandins, leukotrienes, and essential fatty acids.

[17]  Mark A. Smith,et al.  Diabetes‐induced nitrative stress in the retina, and correction by aminoguanidine , 2002, Journal of neurochemistry.

[18]  G. Nisticó,et al.  Spontaneous induction of nitric oxide- and prostaglandin E2-release by hypoxic astroglial cells is modulated by interleukin 1 beta. , 1997, Biochemical and Biophysical Research Communications - BBRC.

[19]  B. Brüne,et al.  The role of nitric oxide and cyclooxygenase-2 in attenuating apoptosis. , 2002, Journal of Environmental Pathology And Toxicology.

[20]  RETINA , 1965 .

[21]  M. Mcdaniel,et al.  Selective inhibition of the inducible nitric oxide synthase by aminoguanidine. , 1993, European journal of pharmacology.

[22]  H. Hammes,et al.  Aminoguanidine inhibits the development of accelerated diabetic retinopathy in the spontaneous hypertensive rat , 2004, Diabetologia.

[23]  Y. Courtois,et al.  Inducible Nitric Oxide Synthase Mediates Retinal Apoptosis in Ischemic Proliferative Retinopathy , 2002, The Journal of Neuroscience.

[24]  M. Alcaraz,et al.  Co-regulation between cyclo-oxygenase-2 and inducible nitric oxide synthase expression in the time-course of murine inflammation , 1999, Naunyn-Schmiedeberg's Archives of Pharmacology.

[25]  J. Cunha-Vaz,et al.  Nitric oxide synthase activity in retinas from non-insulin-dependent diabetic Goto-Kakizaki rats: correlation with blood-retinal barrier permeability. , 2000, Nitric oxide : biology and chemistry.

[26]  Y. Kato,et al.  Involvement of nitric oxide in glucose toxicity on differentiated PC12 cells: prevention of glucose toxicity by tetrahydrobiopterin, a cofactor for nitric oxide synthase , 2002, Neuroscience Research.

[27]  M. Lorenzi,et al.  Accelerated death of retinal microvascular cells in human and experimental diabetic retinopathy. , 1996, The Journal of clinical investigation.

[28]  J. Pelletier,et al.  Nitric oxide induced cell death in human osteoarthritic synoviocytes is mediated by tyrosine kinase activation and hydrogen peroxide and/or superoxide formation. , 2002, The Journal of rheumatology.

[29]  C. Edwards International Textbook of Diabetes Mellitus , 2004 .

[30]  S. Ghosh,et al.  Inhibition of NF-kappa B by sodium salicylate and aspirin. , 1994, Science.

[31]  Yoshiji Yamada,et al.  Interaction Between Nitric Oxide Synthase and Cyclooxygenase Pathways in Osteoblastic MC3T3‐E1 Cells , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[32]  M. O’connor,et al.  The inhibitory effects of mercaptoalkylguanidines on cyclo‐oxygenase activity , 1997, British journal of pharmacology.

[33]  M. Currie,et al.  L-N6-(1-iminoethyl)lysine: a selective inhibitor of inducible nitric oxide synthase. , 1994, Journal of medicinal chemistry.

[34]  H. Kiyama,et al.  Constitutive nitric oxide synthase is associated with retinal vascular permeability in early diabetic rats , 2001, Diabetologia.

[35]  E. Garvey,et al.  Selective inhibition of constitutive nitric oxide synthase by L-NG-nitroarginine. , 1993, Biochemistry.

[36]  J. Morrow,et al.  Peroxynitrite, the coupling product of nitric oxide and superoxide, activates prostaglandin biosynthesis. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[37]  M. Currie,et al.  Regulation of prostaglandin production by nitric oxide; an in vivo analysis , 1995, British journal of pharmacology.

[38]  J. Crabb,et al.  Establishment and characterization of a retinal Müller cell line. , 1998, Investigative ophthalmology & visual science.

[39]  T. Kern,et al.  Pharmacological inhibition of diabetic retinopathy: aminoguanidine and aspirin. , 2001, Diabetes.

[40]  M. Currie,et al.  Nitric oxide activates cyclooxygenase enzymes. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[41]  Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[42]  R. Egan,et al.  Mechanism for irreversible self-deactivation of prostaglandin synthetase. , 1976, The Journal of biological chemistry.